Jim. you afternoon. Good Thank
quarter, first continued in have momentum the XXXX. our build we to on During
to therapies, future pursuit creation. driving As prospects and of we our commitment our enhance innovative our growth capital position we to leverage our long-term will continue strong value
FDA. you, Tradipitant our with February court conduct of remind partial complaint months in Vanda year, not To FDA's a for Tradipitant this the Let us imposition of federal with status on a an to of hold update does in allow studies that in begin the duration. contesting filed and beyond the current three dispute clinical we
rabbits discussed, and kilogram previously dogs been a findings because than because As but for Tradipitant in of two than X,XXX the rats, durations findings. times been of database, Similarly, human to more no specifically dose hold animals, on studies Extensive findings. was already relevant an per conduct months and years for clinical patients insistence in studied administrative the to nine-month up in imposed of XXX unnecessary of not and been Tradipitant safety studies doses an XXX in have duration than three with more has including Tradipitant safety multiples in mice, non-rodents dogs. up completed. significant Tradipitant in has study to no at studied more milligram with extensive
to on its to reevaluation, own FDA XX, grant the mistake, believes the FDA a court's response voluntary response hold potential from remand the a to cure after that Following for that Friday, clinical of The the FDA indicates appropriate. Vanda request partial provided remand XXXX. continues April be
the expedite to joint Tradipitant and scheduling extension requirements to Vanda study number pursue and for continued Propose XXXX continue X, are to options propose resolving law and remove May unnecessary intend Scheduling in partial of sufficient to hold, of safety extending are an of agree motion FDA's FDA evaluating order We believe the matter. trials Monday, of a and we we where same market. XX FDA upon will to vigorously While to clinical and our its these hold, FDA to the month long On focused time a that interests the Tradipitant the FDA the working Vanda remain to April also a justify Time in information we patients the XX, may evaluating us XX beyond until potentially in to a accordance not on FDA clinical other we partial regulations XXXX, with the to the filed we thereby for are disappointed bringing regarding Order. at a clinical with provided deadline that weeks requirement. the insistent allow regulators impose in the applicable geographies conduct Besides have
safety top be priority, safety our our is the today. always drug widespread animals taking achieve we without place can and goals While will of testing
conduct companies is hardly literature FDA public of position that dog safety stance. patients given no continue society clinical scientific add safety to to add its to inform safety to another the understanding value predictive and yet our nine of study to to we or Forcing duration, encourage benefit Extensive will experiments the or conduct no trials. scientific will the existing supports Vanda's any that month value database, of reassess
HETLIOZ Turning our to business.
patients and among to individuals. And this sighted see of efforts driven to our is recognition growth in by initiative. create Non-XX on our We HBI treatment, continue broader awareness
Non-XX. continuing As well as facilitate treatment efforts of we are blind to with our patients
the the launch in are towards jet We for HETLIOZ half working lag second XXXX. commercial of of
also of to in supplemental PDUFA and FDA the file the expects the treatment patients XXXX. third of XX, date SMS regulatory quarter the to HETLIOZ meet in third the August for supplemental confirm forward NDA Vanda a the in to XXXX. path with of NDA reminder, with expects a is As XXXX quarter
Phase of disorder, in mutation in have patients the a who a phase XXXX. plans study specifically in the have CRYX third quarter gene sleep of clinical X also HETLIOZ delayed We initiate for to
clinical a planned that awareness for patients now disorder, Tradipitant. XXXX, is an HETLIOZ atopic begin in program schizophrenia. of the with to other I On study our we benefits will Phase Fanapt, XXXX months are treat of patients preparing positive of ongoing. study Fanapt, psychiatrists In of we greater which on and Tradipitant the with to initiated of HETLIOZ still is in on we ability long-acting advance a among provide in Phase and pharmacokinetic in and formulation individuals for gastroparesis. issues, focused parallel, to the Fanapt number of reported study our injectable X to randomized continues coming Vanda treatment in In confident years. As which the Non-XX in and even in we health study are Tradipitant patients results turn dermatitis the continuing a are of with to X bipolar of driving
to efficacy and we an randomized currently the week safety a dermatitis, XX will in atopic X Tradipitant period placebo a in XXX a fashion. Tradipitant of patients are twice recruiting For day study in which eight or milligrams patients patient during Phase evaluate receive
time, evaluating and include study are of this including be IGA. endpoints, reported At measures topline SCORAD, a daily will expect completed diaries, We will objective that measures itch, worst of as this EZ patient reported be as by that number mid-XXXX. we through well results and
to plans second first quarter dermatitis the in initiate have Phase atopic study X of likely also We XXXX. by the
days. a we of with and reported measure particularly nausea success on reported on number patient positive endpoints, nausea For of the Phase daily free study of measures X results gastroparesis,
We later DDW the San are in this data by upcoming and Conference to at Diego month. encouraged plan these this present results
plan the findings. these during year this also second to quarter study confirm of initiate We to gastroparesis a X in Phase
will weeks our discuss X X program planned with end FDA Phase the We to coming of in our meeting. meet Phase the during
sickness we of have for protocol motion completion first This quarter will quarter sickness. discuss results recently involves a end I to to program with financial treatment we induction nearing current of year. the initiated is indication patients the Finally, the of sickness. third patients history Jim travel This now by by motion of will for Tradipitant results. with of With our study and motion call report the this that, to turn sea third
